Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

4.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

3.1K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discovery of SD-2301 as a Highly Potent and Selective PROTAC STAT3 Degrader Capable of Achieving Complete Tumor Regression with Single Administration.

Journal of medicinal chemistry·2026
Same author

Discovery of SMD-6346: A Potent, Selective, and Orally Active SMARCA2 Degrader for Targeting SMARCA4-Deficient Human Cancers.

Journal of medicinal chemistry·2026
Same author

Targeted degradation of CBP/p300 by CBPD-409 exhibits robust anti-myeloma activity.

Leukemia·2026
Same author

Machine Learning Model Predicts Clinical Adverse Events of Small Molecule Kinase Inhibitors in Cancer Patients Using On-/Off-Target Engagement and Tissue Selectivity.

Clinical pharmacology and therapeutics·2026
Same author

Dual targeting of PI3Kγ and STING overcomes regulatory B cell- and myeloid cell-driven immune suppression in pancreatic cancer.

Nature cancer·2026
Same author

Activity of PROTAC MDM2 degrader in primary leukemia cells and PDX models.

Leukemia·2026

Related Experiment Video

Updated: Apr 25, 2026

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

18.7K

MD-4251: A First-in-Class Oral MDM2 Degrader Inducing Complete Tumor Regression with Single-Dose Administration.

Ranjan Kumar Acharyya1, Liyue Huang1, Angelo Aguilar1

  • 1Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, Michigan 48109, United States.

Journal of Medicinal Chemistry
|June 13, 2025
PubMed
Summary

Researchers developed MD-4251, a novel oral drug targeting MDM2 (a cancer-promoting protein) using PROTAC technology. This drug effectively degrades MDM2, activates p53, and shows promise for treating acute leukemia.

More Related Videos

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
00:07

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.2K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K

Related Experiment Videos

Last Updated: Apr 25, 2026

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

18.7K
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
00:07

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.2K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • MDM2 is a crucial negative regulator of the tumor suppressor p53.
  • MDM2 is a significant therapeutic target in various cancers.
  • Targeting MDM2 offers a potential strategy for cancer treatment.

Purpose of the Study:

  • To report the discovery and characterization of MD-4251, a novel orally efficacious MDM2 degrader.
  • To evaluate the efficacy of MD-4251 in preclinical cancer models.
  • To assess the drug-like properties of MD-4251 for therapeutic development.

Main Methods:

  • Development of MD-4251 using Proteolysis Targeting Chimera (PROTAC) technology.
  • In vitro assessment of MDM2 degradation and p53 activation in cancer cell lines.
  • In vivo studies in mouse models to evaluate pharmacokinetics, pharmacodynamics, and anti-tumor efficacy.
  • Selectivity profiling against p53 mutant cell lines and assessment of drug liabilities.

Main Results:

  • MD-4251 demonstrated potent and rapid MDM2 degradation (DC50 = 0.2 nM) and robust p53 activation in RS4;11 cells.
  • The compound selectively inhibited the growth of acute leukemia cell lines with wild-type p53.
  • MD-4251 exhibited excellent oral bioavailability, favorable metabolic stability, and no significant CYP or hERG liabilities in mice.
  • A single oral dose led to sustained MDM2 depletion and complete tumor regression in vivo.

Conclusions:

  • MD-4251 is the first orally efficacious MDM2 degrader developed using PROTAC technology.
  • MD-4251 effectively depletes MDM2, activates p53, and exhibits potent anti-leukemia activity.
  • MD-4251 represents a promising therapeutic candidate for cancer treatment, particularly for MDM2-dependent malignancies.